← SynDRA
ALISKIREN
SynDRA canonical compound SYN0014414 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | REN |
|---|
| Mechanism of action | Anti-hypertensive agent |
|---|
| Indication | hypertension |
|---|
| Disease area | cardiology |
|---|
All known targets
- REN
- ABCB1
- CYP3A4
- Ren1
- protease
Mechanisms of action (all sources)
- Renin inhibitor
- protease inhibitor
- Peptidase inhibitor
- REN INHIBITOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- ABCC2
- MLNR
- ESR1
- GHSR
- HDAC6
- HRH1
- HRH2
- HRH3
- HTR1A
- HTR2A
- HTR2B
- HTR2C
- HTR3A
- KCNH2
- MAOA
- MC3R
- NPY1R
- ABCC3
- NR1I2
- NR3C1
- OPRD1
- OPRK1
- OPRM1
- PDE3A
- PDE4D
- PGA5
- PGR
- PTGS2
- SLC29A1
- SLC6A2
- SLC6A3
- SLC6A4
- EDNRA
- DRD3
- DRD2
- DRD1
- ABCC4
- ADORA1
- ADORA2A
- ADORA3
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
Drug classes
- Enzyme Inhibitors
- Protease Inhibitors
- Renin Inhibitors
- Renin Inhibitor
- Anti-hypertensive agent
ATC classes
- C09X · OTHER AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
- ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs), COMBINATIONS
Cross-references
Synonyms
- ALISKIREN HEMIFUMARATE
- AMTURNIDE
- TEKAMLO
- TEKTURNA
- TEKTURNA HCT
- Tekturna
- VALTURNA
- rasilez
- tekturna
- aliskiren hemifumarate
- aliskiren fumarate
- SPP100
- Aliskirene
- Aliskireno
- SPP-100
- Rasilez
- SPP 100
- Rasilez (TN)
- Tekturna (TN)
- Aliskiren (USAN/INN)
- aliskirene
- CGP-60536
- CHEBI:601027
- CGP-060536B
- aliskirenum
- RefChem:56248
- C09XA02
- CGP060536B
- DTXCID401030595
- CGP60536
- Aliskiren(CGP 60536)
- MFCD09839018
- CGP60536B
- Aliskiren [INN]
- C30H53N3O6
- NCGC00186464-01
- CGP 60536;CGP60536B;SPP 100
- Aliskiren [USAN:INN:BAN]
Reported adverse events
- Angioedema
- Hypersensitivity
- Hypotension
- Erythema
- Cough
- Urticaria
- Severe cutaneous adverse reaction
- Stevens-Johnson syndrome
- Vomiting
- Nausea
- Seizure
- Blood creatinine increased
Look up ALISKIREN in the interactive SynDRA portal →